세러스 (CERS) 주가 전망: 목표주가, 배당, 최신 뉴스

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment.

It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

Cerus Corporation은 생의학 제품을 개발·상용화하는 회사로, 혈액 안전성을 높이기 위한 INTERCEPT Blood System 개발에 주력하고 있습니다. INTERCEPT Blood System은 기생·미생물의 증식을 제어하는 독자적 기술로, 수혈용으로 기증된 혈액 성분에서 혈액매개 병원체를 감소시키도록 설계되어 있습니다.

제품 포트폴리오에는 수혈용 혈소판과 혈장, 그리고 cryoprecipitation용 INTERCEPT Blood Systems(혈소판과 혈장에 있는 혈액매개 병원체를 불활성화하도록 설계됨), 적혈구용 INTERCEPT Blood System(수혈용 적혈구의 병원체 불활성화용), INTERCEPT Blood System for Cryoprecipitation(자사 혈장 시스템을 이용해 출혈 치료·조절에 쓰이는 병원체 저감 동결침전 섬유소원 복합체를 생산하고, 병원체 저감 혈장 및 병원체 저감 동결침전물을 제공)과 혈액성분 처리용 LED 기반 장치인 INTERCEPT Illuminator가 포함됩니다.

혈소판 및 혈장 시스템은 미국, 유럽, 독립국가연합(CIS), 중동, 라틴아메리카 등지에서 직판 및 대리점망을 통해 판매합니다. 회사는 1991년 설립되었고, 1996년 7월 사명을 CERUS TECHNOLOGIES INC에서 Cerus Corporation으로 변경했으며 본사는 캘리포니아주 Concord에 있습니다.

• 주소: 1220 Concord Avenue, Suite 600, Concord, CA 94520, United States

• 전화번호: 925 288 6000

• 웹사이트: https://www.cerus.com

• 섹터: Healthcare

• 산업: Medical Devices

• 직원 수: 261